| アブストラクト | BACKGROUND: Historically, COPD has been considered to affect mostly older men with a history of smoking; however, in recent times, its prevalence and mortality rates have steadily increased among women. OBJECTIVES: The goal of this study was to systematically assess differences in COPD expression between women and men in UK primary care clinics who were newly diagnosed with COPD. METHODS: This retrospective cohort study compared women and men with an incident diagnosis of COPD by using electronic medical records data from the Clinical Practice Research Datalink and linked Hospital Episode Statistics data. The overall study period was between January 1, 2006, and February 28, 2016; patients with an incident diagnosis of COPD between January 1, 2010, and February 28, 2015, were analyzed. RESULTS: A cohort of 22,429 patients were identified as incident patients and included in the study; 48% of patients with COPD were women. The risk of first moderate or severe exacerbation was 17% greater in women than in men (hazard ratio, 1.17; 95% CI, 1.12-1.23), with a median time to first exacerbation of 504 days for women and 637 days for men. These differences were more prominent in the younger age group (>/= 40 years to < 65 years), as well as in Global Initiative for Chronic Obstructive Lung Disease 2016 groups B, C, and D and in individuals with moderate to severe airflow obstruction. The annual rate of moderate or severe exacerbations was higher in women compared with men in the first, second, and third year of follow-up. CONCLUSIONS: These results highlight the unmet need for appropriate identification and management of women with COPD in clinical practice. |
|---|
| ジャーナル名 | Chest |
|---|
| Pubmed追加日 | 2019/5/20 |
|---|
| 投稿者 | Stolz, Daiana; Kostikas, Konstantinos; Loefroth, Emil; Fogel, Robert; Gutzwiller, Florian S; Conti, Valentino; Cao, Hui; Clemens, Andreas |
|---|
| 組織名 | Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital,;Basel, Switzerland.;Basel, Switzerland; Respiratory Medicine Department, University of Ioannina;Medical School, Ioannina, Greece. Electronic address: ktkostikas@gmail.com.;Novartis Sverige AB, Taby, Sweden.;Novartis Pharmaceuticals Corporation, East Hanover, NJ.;Novartis Pharma AG, Basel, Switzerland.;Novartis Ireland Limited, Dublin, Ireland.;Novartis Pharma AG, Basel, Switzerland; Heart Center Freiburg University,;Cardiology and Angiology I, Faculty of Medicine, Freiburg, Germany. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31103696/ |
|---|
